Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 25, 2026-- Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on

BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 16, 2026-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer

BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 14, 2026-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company.

Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 10, 2026-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare

Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining cash-flow break-even BILLERICA, Mass. --(BUSINESS WIRE)--Aug.

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 6, 2026-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46 th Annual Growth Conference at the Intercontinental Hotel in

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 4, 2026-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results.

BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 16, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the “Inducement Grant”) was made to Jason Faessler in connection with

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD ® Complete multi-biomarker blood BILLERICA, Mass. --(BUSINESS WIRE)--Jul.

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 16, 2026-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement